Want to join the conversation?
$AMGN Amgen today announced that European Commission has granted marketing authorization for Repatha (TM) (evolocumab), the first proprotein convertase subtilisin/kexin type 9 inhibitor to be approved in the world, for treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!